卢卡卡里布的现实世界不成比例分析:营销后药监数据
Qilin Zhang1, Yiling Ding2, Yamin Shu3
1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
这项研究在现实数据中确定了与rucaparib相关的新不良事件 (AE). 需要进一步的研究来证实这些意外的安全信号对于卵巢癌患者.
科学领域:
- 药物监督 药物监督 药物监督
- 在瘤学瘤学.
- 药品安全 药品安全
背景情况:
- 鲁卡帕里布已被批准用于复发的卵巢,输卵管和初级腹膜癌症的维持.
- 以前没有大量人群的长期安全数据.
- 本研究使用现实世界药监数据评估了与rucaparib相关的不良事件 (AE).
研究的目的:
- 评估与rucaparib相关的不良事件 (AE).
- 识别新的和意想不到的AE.
- 分析与rucaparib相关的AE的发病时间.
主要方法:
- 美国FDA不良事件报告系统 (FAERS) 数据的不成比例分析 (2017年1月 - 2022年6月).
- 与rucaparib相关的副作用的特征及其发病时间.
- 在系统器官类 (SOC) 中识别AE信号.
主要成果:
- 在9,296,694份报告中,发现了7,087份与rucaparib相关的AE报告.
- 在15个SOC中发现了135个与rucaparib相关的AE信号.
- 发现了21种新的,意想不到的副作用,包括肠道阻塞和脱水,以及已知的副作用,如贫血和恶心. 中位数AE发病时间为12天.
结论:
- 现实世界的数据表明与rucaparib.相关的潜在的新不良事件.
- 需要进一步的研究来验证这些发现并确认安全性.
- 这些发现有助于了解rucaparib在临床实践中的长期安全性.
更多相关视频
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Analysis of Population Pharmacokinetic Data
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
